Drugs / ABBV-6628
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07160179 | Aug 2025 → Oct 2029 expected | age-related macular degeneration, diffuse secondary choroid atrophy | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-6628 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07160179 ↗ |
| Modality | Monoclonal antibody | “ABBV-6628 is an investigational monoclonal antibody fragment” NCT07160179 ↗ |